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Effects of an Unusual Poison Identify a Lifespan Role for Topoisomerase 2 in
Saccharomyces Cerevisiae
Abstract
A progressive loss of genome maintenance has been implicated as both a cause and consequence of
aging. Here we present evidence supporting the hypothesis that an age-associated decay in genome
maintenance promotes aging in Saccharomyces cerevisiae (yeast) due to an inability to sense or repair
DNA damage by topoisomerase 2 (yTop2). We describe the characterization of LS1, identified in a high
throughput screen for small molecules that shorten the replicative lifespan of yeast. LS1 accelerates
aging without affecting proliferative growth or viability. Genetic and biochemical criteria reveal LS1 to be a
weak Top2 poison. Top2 poisons induce the accumulation of covalent Top2-linked DNA double strand
breaks that, if left unrepaired, lead to genome instability and death. LS1 is toxic to cells deficient in
homologous recombination, suggesting that the damage it induces is normally mitigated by genome
maintenance systems. The essential roles of yTop2 in proliferating cells may come with a fitness tradeoff in older cells that are less able to sense or repair yTop2-mediated DNA damage. Consistent with this
idea, cells live longer when yTop2 expression levels are reduced. These results identify intrinsic
yTop2-mediated DNA damage as a potentially manageable cause of aging.
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ABSTRACT
A progressive loss of genome maintenance has been implicated as both a cause and consequence of aging. Here
we present evidence supporting the hypothesis that an age‐associated decay in genome maintenance promotes
aging in Saccharomyces cerevisiae (yeast) due to an inability to sense or repair DNA damage by topoisomerase
2 (yTop2). We describe the characterization of LS1, identified in a high throughput screen for small molecules
that shorten the replicative lifespan of yeast. LS1 accelerates aging without affecting proliferative growth or
viability. Genetic and biochemical criteria reveal LS1 to be a weak Top2 poison. Top2 poisons induce the
accumulation of covalent Top2‐linked DNA double strand breaks that, if left unrepaired, lead to genome
instability and death. LS1 is toxic to cells deficient in homologous recombination, suggesting that the damage it
induces is normally mitigated by genome maintenance systems. The essential roles of yTop2 in proliferating
cells may come with a fitness trade‐off in older cells that are less able to sense or repair yTop2‐mediated DNA
damage. Consistent with this idea, cells live longer when yTop2 expression levels are reduced. These results
identify intrinsic yTop2‐mediated DNA damage as a potentially manageable cause of aging.
sets of longevity genes, and both have identified
longevity pathways or genes with relevance to
mammalian aging. The standard method for quantifying
replicative lifespan (RLS) is slow and tedious because it
requires the manual microdissection of daughter cells
from their mothers, but see [5, 6]. In this study we
describe improvements to the high throughput capable
Death of Daughters (DeaD) RLS proxy assay [7], and
employ it in a screen for small molecules that shorten
RLS without affecting proliferation or viability.

INTRODUCTION
The longevity of an organism is determined by a
confounding combination of genes and environment.
Lifespan assays in model organisms have identified
numerous longevity genes—those that when mutated or
when over- or underexpressed affect mean and/or
maximum lifespan—with primary roles in many cell
processes, including genome maintenance, metabolism,
mitochondrial function, and oxidative stress [1, 2]. The
lifespan of Saccharomyces cerevisiae (yeast) is
measured using chronological or replicative models,
both of which respond similarly to environmental
interventions such as caloric restriction and oxidative
stress [3]. While there is no correlation between the
chronological and replicative lifespans of natural yeast
isolates [4], the two methods have yielded overlapping
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Here we characterize LS1, a RLS shortening molecule
that acts by poisoning yeast topoisomerase 2 (yTop2).
yTop2 is an essential enzyme that generates transient
double strand breaks (DSBs) in order to relieve positive
and negative DNA supercoils during replication,
transcription and DNA repair, and to separate tangled
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(concatenated) chromosomes prior to mitosis [8]. Top2
poisons stabilize Top2-DNA covalent complexes
(Top2ccs) in which the 5’-phosphate ends of the double
strand break are linked to the enzyme via
phosphotyrosine ester bonds. If left unrepaired Top2ccs
disrupt transcription and replication and lead to genome
instability, senescence and cell death [9, 10]. Top2
poisons include widely used chemotherapeutic drugs,
but are also found in foods and in the environment [11].
DNA abasic sites, alkylated bases, and UV-induced
lesions are also capable of stabilizing Top2-DNA
adducts [11]. This is relevant to the potential role of
Top2 in aging because all of these base modifications
and lesions accumulate in aging cells and tissues [12].
Genetic programs that recognize and repair Top2ccs,
including specific tyrosyl phosphodiesterases and
nucleases [13-15] and DNA repair systems [16, 17],
support the notion that Top2ccs are a normal fact of life.
Chemotherapeutic Top2 poisons kill dividing (cancer)
cells by overloading these remediation mechanisms
with large numbers of Top2ccs.

capacity of the mother cells rather than nutrient
limitation.
The DeaD assay recapitulates lifespan shortening and
extension associated with under- and over-expression of
SIR2 (Fig. S3). The DeaD assay also recapitulates
lifespan shortening by a number of gene deletions
previously shown by microdissection assay to shorten
RLS, including sir2Δ, sgs1Δ, rad9Δ, rad51Δ, rad52Δ,
phb1Δ, and isw1Δ (Fig. S4), but does not show RLS
extension in many strains containing gene deletions
known to extend RLS (including tor1Δ and hxk2Δ).
Therefore, in this report we focused on the
demonstrated utility of the DeaD assay to report RLS
shortening.
High throughput screen for small molecules that
shorten replicative lifespan
Small molecules that reduce DeaD cell growth under
restrictive conditions, but minimally affect growth
under permissive condition, are candidate probes that
target longevity factors. An essential criterion for
meaningful RLS shortening is a lack of toxicity at doses
where statistically significant RLS shortening is
observed. It is not interesting to shorten “apparent”
RLS simply by making cells sick.

The simplest explanation for our results is that LS1 is
selectively toxic to aging cells that have a diminished
capacity to repair Top2ccs. In support of this hypothesis
we show that reducing TOP2 expression is sufficient to
extend RLS. Previous evidence in support of the DNA
damage theory of aging is based on observations and
experiments that link DNA damage to reductions in
longevity. Our results show that native levels of DNA
damage by yTop2 are a direct cause of aging.

The DeaD assay was used to screen a 138,758
compound NIH small molecule library for those that
reduced growth in glucose (restrictive) without
significantly affecting growth in galactose (permissive)
(see PubChem Assay #AID 804). 759 active compounds
were reassessed under both restrictive and permissive
conditions in a 10-point 2-fold dilution series ranging
from 0.098 - 50 μM (see PubChem Assay #AID 849).
The top 44 DeaD lifespan-shortening compounds were
ranked according to their ratios of restrictive
growth/permissive growth (Supplementary Methods).
Here we describe studies on the biological activities and
mechanism of action of LS1 (6H-Indolo [2,3-b]
quinoxaline: SID 4264584).

RESULTS
Death of Daughters (DeaD) assay recapitulates
aspects of replicative aging
The DeaD assay is a high throughput proxy for the
standard RLS microdissection assay, which is slow and
labor intensive [7]. The DeaD assay is based on the
W303R derived strain K6001 that was engineered to
study mother cell specific mating type switching [18,
19]. As described in the Supplementary Data we
reconstructed and greatly improved the performance of
the original DeaD strain (Supplemental Figs. S1, S2 &
S3). DeaD strains contain two chromosomal copies of
the essential CDC6 gene, one under the control of the
inducible GAL1 promoter and the other under the
control of the mother-specific HO promoter. In
galactose-containing medium, both mothers and
daughters express CDC6, predominately from the GAL1
promoter, and divide exponentially. In glucosecontaining medium, daughter division is strongly
inhibited due to the lack of expression of CDC6 from
either promoter, and the growth rate and saturation
point of the culture becomes limited by the reproductive
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LS1 is a potent lifespan shortener
In yeast, nicotinamide (NAM) shortens RLS largely due
to the compound’s activity as a feedback inhibitor of
Sir2, though it inhibits other yeast sirtuins that affect
lifespan and also prevents lifespan extension by caloric
restriction by a sirtuin-independent mechanism [20-22].
As shown in Fig. 1A, NAM shortens DeaD lifespan at
concentrations (IC50 = 1 mM) where it has no
discernable effect on permissive growth. Similar to
NAM, LS1 also exhibits dose-dependent DeaD lifespan
shortening (DeaD IC50 = 5 μM) at concentrations where
permissive growth is unaffected (Fig. 1B), though it is
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~200-fold more potent than NAM. The DeaD assay
RLS shortening activity of 1 μM LS1 was confirmed by
standard microdissection assay (Fig. 2).

pathway, for example, by directly or indirectly
inhibiting Sir2, we assessed the effects of LS1 in
fob1Δ and sir2Δ strains. As shown in Fig. 3A, LS1
effectively reduced DeaD lifespans in both fob1Δ and
sir2Δ strains.
In contrast, NAM, which acts
predominately by inhibiting Sir2, shows significantly
less DeaD lifespan shortening activity in fob1Δ and
sir2Δ strains (Fig. 3B). The modest lifespan reduction
by NAM in fob1Δ and sir2Δ strains may be due to its’
sirtuin-independent RLS-shortening activities [22]. We
conclude that LS1 shortens RLS by an ERC- and Sir2independent mechanism.

LS1 acts independently from the role of Sir2 in ERC
accumulation
The RLS of yeast is normally limited by the agedependent accumulation of extrachromosomal rDNA
circles (ERCs) [23]. ERC formation requires Fob1 and
is suppressed by Sir2 activity [24, 25]. Thus fob1Δ cells
are resistant to the lifespan shortening effects of SIR2
deletion and NAM [24]. To test whether LS1 acts in this

Figure 1. Small molecule effects on DEAD lifespans. Growth rates of DEAD strain (BB579)
in the presence of increasing concentrations of nicotinamide (NAM) (A), LS1 (B), ellipticine
(ELLIP) (C) and doxorubicin (DOX) (D) under nonpermissive (●) and permissive (○) conditions.
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Figure 2.

LS1 shortens replicative lifespan by standard microdissection assay.

Microdissection in the presence and absence of 1µM LS1 was performed as described in Materials and
Methods. LS1 treated (●) FY839 cells had an average lifespan of 16.1 generations, a 41.5% drop from
the untreated sample (○). Graph shows combined data from two independent FY839 colonies.
Superimposed over the experimental data are modeled data showing the effect on the lifespan of the
untreated sample of adding 1% (∆), 2% (○) and 3% (□) non‐age‐related cell death/generation.

Figure 3. Lifespan shortening activity of LS1 is independent of 2μ circles and Sir2. DEAD
assays were performed in the presence and absence of 5µM LS1 (A) or 1mM NAM (B) in parental
(BB579), fob1∆, or sir2∆ strains as described in Materials and Methods. Data represent the average of
three biological replicates. Error bars represent standard deviation.

LS1 is toxic
recombination

in

cells

lacking

for homologous recombination. Specifically, LS1 caused
a slow growth phenotype in rad51Δ, rad52Δ, rad54Δ,
rad57Δ, and mre11Δ cells. LS1 had no vegetative growth
effect on yku70Δ or yku80Δ cells that are defective in
DSB repair by nonhomologous end joining (NHEJ) (Fig
4A). Thus HR, but not NHEJ, is necessary for resistance
to LS1. FACS analysis revealed that LS1-treated rad52Δ
cells tended to arrest growth at G2/M (Fig. 4B). Parental

homologous

To gain insight into the mechanism of action of LS1 we
performed a genome-wide chemical-genetic screen for
deletions of nonessential genes that caused slow growth
in the presence of LS1. This screen identified a set of
genes belonging to the RAD52 epistasis group required
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poisons [26]. top1Δ mutants are hypersensitive to Top2
poisons because these cells rely on Top2 for all
topoisomerase functions that are normally shared by
Top1 and Top2 [9, 10, 27]. Thus the sensitivity of top1Δ
cells is fully consistent with LS1 being an yTop2 poison.

cells treated with LS1 did not show a cell cycle
phenotype. The growth defect of top1Δ cells in the
presence of LS1 was of interest, since the only class of
DNA damaging agents that have been reported to result
in enhanced growth defects in top1Δ mutants are Top2

Figure 4. Synthetic genetic interactions of LS1 with RAD52 epistasis group deletions. A comprehensive
screen of the non‐essential deletion collection revealed synthetic growth defects of LS1 together with deletions of
genes required for homologous recombination. (A) Three‐fold dilutions (starting at 0.1 OD600) of log phase growing
cultures of parental (BY4741) and deletion strains were plated at 30oC for 48 h onto SCD agar containing 0.1% DMSO
vehicle (control) without or with 10µM LS1. (B) DNA content by flow cytometry of LS1 treated parental BY4741 and
rad52∆ cells. Log phase liquid cultures were treated with 0.1% DMSO vehicle (control) without or with 10µM LS1 for
6h followed by fixation with ethanol and propidium iodide staining as described in Materials and Methods.
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exhibits strong lifespan shortening activity in old cells
could be due to an age-associated decrease in the
capacity of older cells to sense and repair LS1-induced
DNA damage. It follows that the lifespan shortening
activity of LS1 could be explained by an age-dependent
decline in DNA repair systems [2, 30]. We hypothesize
that LS1 is selectively toxic in older cells that have
diminished capacity to efficiently either sense or repair
LS1-induced DNA damage.

Figure 4. Synthetic genetic interactions of LS1 with
RAD52 epistasis group deletions. (C) Quantitative effect of
increasing concentrations of LS1 on cell viability in log cultures of
RAD52 and rad52∆ cells. Quantitation of cell viability is
described in Materials and Methods.

The synthetic growth defect of LS1 in rad52Δ cells is
quantified in Fig. 4C and shows that the slow growth
phenotype of RAD52+ cells at very high LS1
concentrations is not due to cell death (Fig. 1B).
Interestingly, these data show that in the absence of LS1
rad52Δ log cultures contain a steady state level of ~2%
dead cells compared with less than 0.5% in RAD52+
cultures (Fig. 4C). Although a death rate of ~2% per
generation would be undetectable by standard methods
used to quantify growth, these levels are amplified in
RLS studies. Adding 1%, 2%, or 3% non-age-associated
cell death/generation reduces the mean RLS of parental
cells by 19%, 31% and 45%, respectively (Fig. 2).
Therefore, the observed ~30% reduction in mean RLS
caused by 1 μM LS1 could be explained if LS1 killed
~2% of cells/generation. In fact, LS1 had an
insignificant effect on the numbers of dead cells in
exponentially dividing cultures, which carry about 0.5%
dead cells/generation, even at concentrations as high as
50 μM (Fig. 4). Steady state levels of age-independent
cell death in log phase rad52Δ cultures could be
responsible for the significant fraction of the published
short RLS of this and other purportedly short-lived
strains [28]. Numbers of nonviable rad52Δ cells
increased dramatically during stationary phase (not
shown), consistent with the report that RAD52 is
required for full chronological lifespan [29]. We
conclude that the shorter RLS of LS1-treated cells is not
due to low levels of non-age-related cell death, as may
be the case for strains such as rad52Δ.

Figure 5. Overexpression of TOP2 confers hyper‐sensitivity
to LS1. (A) Effect of LS1 on BY4741 transformed with high copy
number Yeast Tiling collection plasmids encoding TOP1, TOP2 or
TOP3 (pTOP1, pTOP2, and pTOP3). Threefold‐dilutions of log phase
cells were patched onto YPD medium containing vehicle DMSO
(control) or 10µM LS1. Overexpression of TOP2 was confirmed by
quantitative western blot using secondary antibodies conjugated
to infrared excitable fluorescent dyes and developed using the LI‐
COR fluorescent imaging system (not shown). (B) Quantitative
effect of LS1 concentrations on growth of TOP2 overexpressing
strain compared to cells containing the empty vector. Maximum
growth rates were calculated from triplicate growth curves
generated using a BioScreen C system and BGFit webserver as
described in Materials & Methods.

Together, these results suggest that the lack of toxicity
of LS1 toward young cells at concentrations where it
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numbers of cleavage complexes and are, therefore, more
sensitive to poisons [26]. Consistent with LS1 being a
Top2 poison, over-expression of TOP2, but not TOP1
or TOP3, increased LS1 toxicity (Fig. 5A). The dosedependent toxicity of LS1 in cells expressing native or
many-fold higher levels of yTop2 is also consistent with
a Top2 poisoning mechanism (Fig. 5B). Interestingly,
even at high concentrations LS1 did not completely
inhibit growth in cells expressing native levels of
yTop2. This is interesting because yeast TOP2 is an
essential gene, so strong inhibition should either be
lethal or at least cause strong growth defects. It is
possible that the cell’s repair and remediation pathways
cope with a limited number of LS1-induced Top2ccs
and, in the steady state, regenerate a sufficient pool of
Top2 to perform essential roles. In contrast, doxorubicin
and ellipticine completely inhibited growth of cells
expressing native TOP2 levels (Fig. 1C & D). Higher
concentrations LS1 had even greater inhibitory effects
on the growth of cells overexpressing TOP2, indicating
that presumptive remediation pathway(s) can be
overwhelmed (Fig. 5B).

LS1 is a TOP2 poison
LS1 is basically the unsubstituted scaffold of ellipticine,
a Top2 poison [31, 32]. If LS1 were simply a weak
Top2 poison, then other Top2 poisons dosed at subtoxic
concentrations might also reduce RLS. Two structurally
distinct Top2 poisons, ellipticine and doxorubicin, were
tested using the DeaD assay for RLS shortening
activity. Ellipticine and doxorubicin shorten apparent
DeaD lifespan simply by virtue of their being cytotoxic
(Fig. 1C & D).
We performed a simple in vivo test for yTop2 poisoning
by LS1. Because yTop2 participates directly in the
formation of cleavage complexes, cells expressing
higher levels of yTop2 have the potential to form greater

Based on these in vivo results we directly tested LS1 for
inhibition of Top2 enzyme activity. Fig. 6A shows that
LS1 inhibited kinetoplast DNA decatenation by human
Top2α (IC50 = 3 μM). Unlike some Top2 poisons,
including ellipticine and doxorubicin, LS1 did not
detectably intercalate into DNA (Fig. 6B). This finding
is consistent with a previous study concluding that LS1
does not bind DNA in contrast to other quinoxaline
analogs [33]. A lack of DNA binding or intercalation
ability does not by itself explain the lack of toxicity of
LS1, since etoposide, another well studied,
nonintercalating Top2 poison is cytotoxic.
Top2 poisons induce the accumulation of DSBs, either
by promoting the formation of Top2cc adducts or by
slowing their re-ligation, making them aberrantly longlived. Parenthetically, bisdioxopiperazines such as
ICRF-193 promote non-covalent but tightly bound Top2
which are toxic because they interfere with transcription
and other DNA metabolic processes; however, because
the toxicity of these molecules is not enhanced by
mutations in the RAD52 pathway it is unlikely that
DSBs are generated [34, 35]. In support of the
conclusion that LS1 is a true Top2 poison, we show that
Figure 6. LS1 is a nonintercalating TOP2‐α inhibitor. (A) Effect of LS1 on decatenation of C. fasciculata kinetoplastid DNA (kDNA) by
purified human TOP2‐α. Inset shows a negative image of the ethidium bromide stained agarose gel separating kDNA species. Quantitation
of decatenated kDNA was done with GelQuant.NET 1.8.2 software and results were plotted using KaleidaGraph 4.1.0 software. (B) A DNA
topoisomerase I (Top1) DNA unwinding assay was used to assess the ability of LS1 to intercalate as indicated in Methods. Known Top2
poisons that either intercalate (doxorubicin) or do not (etoposide) were included as controls. An E. coli‐compatible plasmid (puc18)
exhibiting both supercoiled (*) and nicked/relaxed (**) forms was used as the substrate (lane 1). In the absence of an intercalator (lane 2)
Top1 converts the plasmid to fully nicked/relaxed (**) or intermediate relaxed forms (***). Intercalation was assessed for DOX (10µM or
50µM; lanes 3‐4), ELLIP (100µM; lane 5), 100mM ETOP (lane 6) and LS1 (10µM, 50µM, or 100µM; lanes 7‐9).
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and absence of 0 -100 μM LS1 in yeast cells expressing
native or overexpressed levels of TOP2. In cells
expressing native levels of Top2, etoposide exhibited
little toxicity with or without LS1 (Fig. 8A). As
expected from a Top2 poison, etoposide exhibited a
strong dose-dependent toxicity in cells overexpressing
TOP2 (Fig. 8B). A physiologically relevant concentration of 10 μM LS1, which alone caused less than ~2fold cell death in TOP2 overexpressing cells, enhanced
1 or 5 μg/ml etoposide toxicity by 10 and 8-fold,
respectively.
We hypothesize that LS1 enhances
etoposide toxicity by transiently stabilizing Top2ccs
that serve as good targets for etoposide poisoning.

LS1 promotes the in vitro formation by yTop2 of DSBs
in plasmid DNA (Fig. 7A & B), albeit less efficiently
than etoposide.
LS1 enhances the potency of chemotherapeutic Top2
poisons in yeast and cancer cells
We hypothesized that LS1 induces the formation of
Top2cc adducts that, in the absence of robust
homologous recombination, cause cell death by the
same mechanism—DNA damage—as classic Top2
poisons. However, unlike other Top2 poisons, LS1 is
not toxic at concentrations where it has strong effects on
RLS (Fig. 1B). We reasoned that LS1-Top2ccs might be
more prone to lethal poisoning by a second more toxic
poison. Thus LS1 could at least transiently target Top2
to DNA, effectively increasing the target population for
attack by lethal Top2 poisons. As a test we quantified 0,
1 & 5 μM etoposide-induced cell death in the presence

Based on the enhancement of etoposide cytotoxicity in
yeast, we asked if LS1 might enhance the toxicity of
Top2 poisons to human cancer cells. Doxorubicin is a
frontline chemotherapeutic for both solid and liquid
tumors. Enhancers have been sought because lifetime

Figure 7. LS1 induces double strand breaks. (A) A pUC18 plasmid linearization assay was used to determine
if LS1 is capable of promoting formation of Top2cc containing double strand breaks. Assays were performed as
described in Materials and Methods. (B) Percent linearized DNA quantified with GelQuant.NET 1.8.2 software.
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doses of doxorubicin are limited by cardiotoxicity [36,
37]. As a test of principle, human HT1080 fibrosarcoma
cells were incubated with or without increasing
concentrations of doxorubicin. As shown in Fig. 9A &
B, LS1 alone is nontoxic to HT1080 cancer cells, but it
enhances cell killing by doxorubicin up to fivefold. In
contrast, LS1 did not enhance the toxicity of
doxorubicin to noncancerous HCA2T human primary
foreskin fibroblasts (Fig. 9C). LS1 also enhanced
etoposide toxicity in HT1080 cells (data not shown).
The fact that LS1 enhanced the toxicity of Top2 poisons
in both yeast and human cancer cells indicates that it
acts by poisoning Top2 in both species.
The
stimulatory interaction between LS1 and two
chemically distinct Top2 poisons supports our
conclusion that the physiological target of LS1 is Top2.
We considered the possibility that LS1 might increase

the potency of doxorubicin and etoposide by inhibiting
multidrug resistance (MDR) pumps such as Pglycoprotein. Inhibition of P-glycoprotein increases
intracellular concentrations of a broad range of
xenobiotics, including vinblastine, resulting in greater
drug potencies [38]. Since LS1 did not increase the
toxicity of vinblastine in HT1080 cells (Fig. 9A, right
panel) we conclude that the enhancement of
doxorubicin toxicity by LS1 is not due to direct or
indirect inhibition of MDR pumps.
Reducing Top2 activity extends RLS
The above results are consistent with the hypothesis that
LS1 enhances the potency of Top2 poisons in both yeast
and human cancer cells by increasing the effective
concentration of Top2 and it’s intrinsic DNA damage-

Figure 8. LS1 enhances killing of yeast by etoposide. LS1 enhances etoposide (ETOP) cytotoxicity
in cells overexpressing TOP2. (A) Cells expressing native levels of TOP2 are not sensitive to ETOP in the
presence of LS1. Cells contained an empty CEN plasmid Ycp50. (B) Overexpression of TOP2 (YCPpDED1‐
TOP2) increased sensitivity to ETOP in the presence of LS1. Yeast strain YMM10 [80], which contains
gene deletions in several drug efflux pumps, was used to promote ETOP sensitivity.
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causing activity. This model suggests that reducing
yTop2 activity could reduce intrinsic levels of DNA
damage and actually extend RLS. Investigating the
effects of reducing yTop2 levels must take into account
that TOP2 is an essential gene in yeast, and that both
its’ strong over- and under-expression cause growth
defects [39, 40]. The first approach we took was to
quantify DeaD lifespans of novel hypomorphic top2
point mutants that were isolated by virtue of being
resistant to LS1 (Fig. 10A), but exhibited no growth
defects (not shown). These point mutations mapped to
diverse sites within the protein (Fig. S6). Cell extracts
from a number of these strains showed several-fold
reduced yTop2 decatenation activities (Fig. 10B). As

shown for one, top2-28 (Fig. 10C), all of these mutants
conferred resistance to doxorubicin, ellipticine and
etoposide. The properties of these mutants are
consistent with previously characterized hypomorphic
alleles that, as would be expected from general loss of
function mutations, confer resistance to multiple Top2
poisons [41-43].
As shown in Fig. 11A, top2-28 cells, which express
reduced yTop2 activity (Fig. 11B), exhibited a
significantly longer DeaD lifespan when compared to
cells expressing wild type TOP2 (Fig. 11A). To validate
and extend these DeaD assay results, we performed
microdissection assays on a strain encoding an under-

Figure 9. LS1 enhances doxorubicin killing of HT1080 fibrosarcoma cells. (A) Cytotoxicity was measured in
HT1080 cells for LS1 (left panel), DOX (middle panel), or vinblastine (right panel). (B) LS1 enhances killing of HT1080 cells
at several concentrations of DOX. Experiments were performed as in (A). (C) Effect of LS1 on a primary human foreskin
fibroblast cell line HCA2T that has been immortalized by transformation with the catalytic subunit of telomerase. HT1080
and HCA2T cells were seeded at low density. After 24 hours, cells were treated with DMSO (vehicle control) or DMSO
containing DOX at the indicated concentrations without or with 10µM LS1. DMSO and DOX data were based on the
average of 6 biological replicates. Vinblastine data was based on three biological replicates. Average values and standard
deviation of the mean are plotted where available. P‐values determined by student t‐test are shown for DOX.
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expressing TOP2-DAmP gene [44]. This strain
expresses native TOP2 at approximately 30% wild-type
levels (Fig. 11C), but exhibited no apparent growth
defect (not shown). Since the haploid strain containing
the TOP2-DAmP allele was generated from the
heterodiploid and compared to the haploid strain
containing the TOP2 wild-type allele, the strains were
isogenic except at the TOP2 locus. As shown in
Fig.11D, constitutively reducing yTop2 levels extended
both mean and maximum RLS.

DISCUSSION

The budding index of the terminally senescent mothers
from the microdissection assays revealed that TOP2DAmP cells tended to arrest more frequently as unbud-

We describe novel biological properties of a drug-like
molecule identified in a high throughput DeaD assay
screen for compounds that shorten yeast RLS. LS1 was

ded (G1) cells (Fig. 11E). Low budding indexes of
senescent mother cell populations indicate robust
growth control at G1/S checkpoints, and correlate with
longer microdissection [28] and microfluidics-based
RLS assays [45-47]. Therefore, wild type levels of
yTop2, which are presumably tuned to optimize
proliferative growth, are deleterious in aging cells—a
phenomenon known as antagonistic pleiotropy [48, 49].

Figure 10. top2 hypomorphic mutants confer resistance to LS1 and other Top2 poisons. LS1 resistant
top2 mutants were selected as described in Methods and Methods using the host JN394 top2ts2‐4 rad52∆ strain in
combination with hydroxylamine mutagenesis of the YCpDED1‐TOP2 plasmid that complements the chromosomal
top2ts2‐4 allele. (A) LS1 sensitivity of four representative LS1 resistant top2 alleles. Growth rates were determined
using the BioScreen C system and fit using the BGFit web‐server as described in Materials and Methods. LS1
resistant top2 alleles also confer resistance to other Top2 poisons. (B) Cell extracts from strains LS1 resistant top2
alleles exhibit reduced Top2 activity using the kDNA assay. (C) top2‐28 cells exhibit increased resistance to multiple
Top2 poisons, including LS1, ellipticine (ELLIP), etoposide (ETOP) and doxorubicin (DOX). All poisons were used at a
concentration of 50µM and growth rates were compared to control (0.1% DMSO) and determined as in panel (A).
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originally described as the unsubstituted scaffold used
in the development of less cytotoxic analogues of
ellipticine [32]. In vivo and in vitro evidence show that
LS1, like ellipticine, is a Top2 poison, albeit weaker and
significantly less cytotoxic. LS1 exhibits none of the
cytotoxicity to cancer (or normal) cells that ellipticine
and other chemotherapeutic Top2 poisons show. LS1
inhibits the in vitro decatenation activity of human
TOP2-α, and induces yTop2 to generate stable DSBs
(Top2ccs) in plasmid DNA. Like known Top2 poisons,
LS1 is toxic to cells overexpressing TOP2 and to cells
deleted for RAD52 epistasis group genes. The latter
synthetic interaction indicates that homologous
recombination is needed to repair Top2ccs formed in
the presence of LS1, and suggested the hypothesis that
LS1 is toxic to aging cells, which, like young
rad52Δ cells, may exhibit a diminished capacity to
recognize and/or repair Top2ccs.

A key finding in our study is that yeast cells live longer
when expressing reduced levels of yTop2. We propose
that the Top2 poison activity of LS1 accelerates aging
by presenting higher than normal Top2cc levels to aging
cells with declining genome maintenance systems [1417]. It follows that decreasing yTop2 levels would
extend RLS by reducing DNA damage to levels below
that which cause normal rates of senescence. The idea
that Top2 is a natural source of DNA damage is not
new. Top2-mediated DNA damage has previously been
implicated in physiologically normal processes [11]. In
mammals, TOP2β-induced DSBs are necessary for the
regulated transcription of neuronal early-response genes
[50] and for TOP2β mediated androgen-induced DNA
rearrangements in prostate cancer [51]. C. elegans top-2
is also responsible for a striking increase in DNA
damage during zygotic genome activation [52]. The
massive induction of transcription that accompanies

Figure 11. Reduced Top2 activity extends replicative lifespan. (A) DeaD cells expressing top2‐28
displayed a roughly two‐fold increase in lifespan both in the absence or presence of LS1 compared to cells
expressing native TOP2. (B) Anti‐Top2 immunoblot of cell extracts from TOP2 and top2‐28 expressing DeaD
strains, using anti‐G6PDH as the loading control. (C) Anti‐Top2 immunoblot of cell extracts from Top2‐DAmP and
TOP2 strains using anti‐G6PDH as the loading control. (D) Microdissection RLS assays of isogenic haploid strains
expressing either Top2‐DAmP or TOP2, obtained by sporulation the heterodiploid. (E) Budding indexes of terminal
mother cells taken from the microdissection RLS assays of Top2‐DamP and TOP2 strains shown in panel C.
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entry of larval primordial germ cells into the cell cycle
triggers widespread DNA damage and activates DNA
damage checkpoints that slow entry into mitosis.
Remarkably, reducing top-2 expression both reduced
levels of DSBs in germ line cells and accelerated their
entry into mitosis, presumably by precluding the need
for the DNA damage checkpoint. This phenomenon
provides a precedent for our hypothesis that a reduction
in yTop2 expression decreases DNA damage in old
cells and extends RLS. As suggested by an apparent
loss of checkpoint control and increased rates of loss of
heterozygosity (LOH) in the daughters of old mothers
[53, 54], old yeast cells proceed through mitosis before
damaged chromosomes can be repaired.

failing to properly repair Top2ccs or by failing to
efficiently activate the DNA damage checkpoint and
stalling the cell cycle until the damage can be repaired.
As described above, older diploid yeast mother cells
switch to a state of high genome instability that
continues to produce high levels of LOH in daughters
until the mothers die [53, 54]. LOH in the daughters of
older mother cells is primarily due to damage-prone
breakage induced repair (BIR) of DSBs. Moreover,
unlike young cells that delay the cell cycle in order to
repair DSBs, old mothers that produce daughters with
LOH do not exhibit cell cycle delay or arrest, consistent
with a loss of the DNA damage checkpoint [53, 54].
These studies argue that LOH in aging yeast arises not
from an increase in the rate of DNA damage, but rather
in the loss of genome maintenance systems needed to
repair damage. Increased genomic instability in the
form of LOH also rises dramatically during chronological aging. Interestingly, although chronological and
replicative lifespans of natural isolates are not
correlated [4], variability among natural isolates in the
lag between the rise in LOH and loss of viability during
chronological aging does correlate with the RLS of
natural isolates, and argues that the capacity to resist
genome instability contributes to natural variation in
RLS [55-57]. LS1 does not affect chronological
lifespan (M. Weinberger and W. Burhans, personal
communication), consistent with the notion that Top2
poisoning by LS1 is selectively toxic to replicating
cells, presumably by interfering with genome
maintenance during and following DNA replication.

Proving that a molecule selectively shortens RLS is
challenging because even low levels of toxicity—either
cytotoxic or cytostatic—will reduce apparent RLS by
arresting cell division irrespective of age. An effective
lifespan shortening agent should have little effect on the
physiology of log-phase cells, ~87% of which are 3
generations or younger, even when the target is an
essential housekeeping factor like yTop2. As is the case
with many drugs that target physiologically important
targets, the dose-dependence of lifespan shortening
compounds is critical to limiting the toxic side effects
associated with targeting essential longevity factors.
LS-1 does become toxic at very high doses, possibly
due to over-inhibition of yTop2 or off-target effects, or
a combination of both. The initial DeaD screen included
both permissive and nonpermissive assays that provided
a filter to exclude molecules such as doxorubicin and
etoposide that are toxic under permissive conditions
(Fig. 1C & D). In contrast, LS1 and NAM reduce DeaD
lifespan at concentrations that have no apparent effects
on permissive growth. Besides having no effect on
growth rate, LS1 has no discernable effects on either the
cell cycle or viability. The viability criterion is
important because even low levels of nonage-associated
cell death cause significant decreases in apparent RLS
using the microdissection assay.
For example,
rad52Δ cells, which had previously been argued to be
short-lived [28], died in log phase at a rate of
~2%/generation. A 2% cell death rate has a negligible
impact on proliferative growth, but reduces mean RLS
by ~30%. LS1 has no detectable effect on cell viability
even at concentrations 70-fold higher than were
sufficient to reduce RLS by ~30%. We conclude that
LS1 is a bona fide lifespan-shortening probe that is
~200-fold more potent than NAM.

Are our results consistent with what others have
observed in aging yeast? Whereas Hu et al. [58]
observed numerous genome rearrangements in older
mother cells, Kaya et al. [55] sequenced the genomes of
colonies produced by daughters of individual old
mother cells and found only low numbers of mutations,
effectively ruling out the accumulation of mutations in
the mothers as the cause of senescence. Our results are
consistent with both of these studies. A single
unrepaired DSB in a mother cell that has lost the
capacity to either sense or repair the damage can be
lethal. This type of damage would not manifest itself as
DNA damage in the genomes of daughter cells.
Accordingly, in the case of yTop2-mediated DNA
damage, it is not the accumulation of mutations that
leads to senescence, but rather as few as a single
catastrophic DSB—those not transmitted to daughters
because the mothers die—that lead to age-associated
cell death.

An age-associated decline in genome maintenance
creates a situation where otherwise manageable levels
of DNA damage become toxic. We propose that LS1 is
selectively toxic to older cells that have lost the capacity
to mitigate yTop2-induced DNA damage, either by
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Our observation using microdissection RLS assays that
terminal mothers under-expressing TOP2 exhibit a
higher frequency of arrest as unbudded G1/S cells
compared to normal cells is consistent with improved
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checkpoint function. Consistent with the idea that
normal levels of yTop2 cause RLS-limiting DNA
damage and loss of growth control, Delaney et al. [28]
reported that mutations that cause defects in genome
stability genes tend to shorten RLS and increase the
proportion of mothers that senesce as budded cells.
Moreover, there is a strong statistical correlation
between RLS and the budding index of terminal
mothers, the latter of which can vary between ~25-70%.
Since not all mothers senesce as budded cells, it is
unlikely that DNA damage and loss of growth control is
the only mechanism that limits RLS in yeast. Thus we
conclude only that yTop2-induced DNA damage
contributes to aging.

theories depend on the assumption that AP genes or MA
alleles escape natural selection because their phenotypes
manifest post-reproductively. Our results indicate that
yeast TOP2 is an AP gene. If we assume that DNA
damage by yTop2 occurs at approximately constant
rates throughout yeast lifespan, then the AP properties
of TOP2 require an age-associated decline in genome
maintenance similar to that which produces LOH in the
daughters of old mother cells. This scenario is
inconsistent with the MA theory of aging because most
of these deleterious mutations would be deleterious
whether they occurred early or late in life. In any case,
Kaya et al. [55] did not find a significant accumulation
of age-associated mutations. Thus our results with
yTop2 support the AP theory of aging. yTop2 activity is
required for proliferation in young cells, but it becomes
toxic late in life. Thus yTop2 is indirectly antagonistically pleiotropic as its effect on longevity
depends on an age-associated decline in genome
maintenance. If correct, the AP effects of TOP2 could
be mitigated late in life, either by moderately reducing
TOP2 expression to levels that do not affect
proliferation, which we have shown to be possible, or
by enhancing repair or damage sensing and checkpoint
systems later in life. In addition to yTop2, other DNA
cleaving or modifying enzymes that have potential to
cause DNA damage with AP properties such as
Topoisomerase 1 [70, 71] may contribute to aging and
age-associated diseases.

Beyond studies in yeast, genome instability or defects in
genome maintenance are strongly correlated with aging
[2, 12, 59, 60]. Strong evidence in support of the DNA
damage theory of aging includes progeroid syndromes
in humans and rodents that are associated with
mutations that affect genome maintenance (reviewed in
[2]). Additional evidence comes from studies showing
that DNA repair systems decline in older animals [6163]. The specific role of DSBs in aging is supported by
the appearance of age-associated phenotypes in mouse
liver following the selective induction of DSBs in that
tissue [64]. Age-associated defects in growth signaling,
resulting in inappropriate entry into S-phase before
DNA damage can be sensed and repaired, or before
adequate stores of nucleotides are available, can lead to
catastrophic events such as replication fork collapse and
irreparable arrest at G2/M [65]. But these observations
do not address whether DNA damage is cause or
consequence of aging. What has been lacking in support
of the DNA damage theory of aging are cases, such as
we show in the case of yTop2, where lifespan is
extended by reductions in DNA damage or by increases
in repair systems or DNA damage checkpoints. Some
evidence, such as the extended lifespan of male mice
that overexpress SIRT6 [66], which is known to
increase expression of DNA repair systems [67], are
confounded by the pleiotropic roles of SIRT6 [68].
Similarly, RLS extension in yeast by overexpressing
histones, which normally become depleted by about
50% in aging yeast, results in a global increase in
transcription, suggests that this form of decline in
genome maintenance plays a role in aging and,
importantly, can be mitigated [69].

MATERIALS AND METHODS
Strains and LS1 chemical-genetic interactions
Negative chemical-genetic interactions with LS1 were
initially determined by replica plating spots of similarly
diluted mid-log cultures of the Yeast deletion collection
library (GE Life Sciences; [72, 73]) on SCD and SCGal
media lacking or containing 20µM LS1. Any patch
showing less growth was confirmed more thoroughly by
replica plating a series of spot dilutions of log-phase
(OD600=1.0) cultures on media containing either
DMSO (0.1%) in the absence or presence of various
concentrations of LS1. To test if LS1 is a topoisomerase poison, high copy number plasmids from the
Yeast Tiling Collection (Thermo Scientific) containing
TOP1, TOP2, and TOP3 genes were isolated and
transformed into the parental yeast strain BY4741 using
Li-acetate/PEG with LEU2 as the selectable marker.
[74].

The antagonist pleiotropy (AP) theory of aging posits
that the normal activities of some genes are beneficial
during development and reproduction, but, for whatever
reason(s), promote senescence later in life [48, 49]. The
mutation accumulation (MA) theory posits that aging
results from the accumulation of mutations that are
selectively deleterious only late in life [48, 49]. Both
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Low to moderate throughput liquid culture DeaD
assays
Strains carrying the three DeaD assay loci
(GAL1:CDC6, HO:CDC6, and the partial deletion of
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the ASH1 promoter) are grown two days on YP/2%
galactose agar plates. A single colony of each strain is
suspended in water and used to inoculate small (1-3
mL) cultures in SCRafGal (SC/ 1.9% raffinose/ 0.1%
galactose, USBiologicals, Swampscott MA) for
overnight growth to early log phase (to ensure early log
phase by the next day, we typically do parallel
inoculations at calculated optical densities (600nm) of
0.0001, 0.00003, and 0.00001). After overnight growth,
one culture of each strain is used to inoculate SC/2%
glucose and SCRaffGal at a calculated OD600 of
0.0001. Using a BioScreen C plate reader (Growth
Curves USA, Piscataway NJ), cultures are grown at
30°C for 3 days, with an optical density (600 nm)
reading taken every 20 minutes.

pDED1-yTOP2 mutagenized plasmids were also
rescued from strains showing resistance to LS1,
transformed into naïve JN394t2-4 and re-tested for
resistance to LS1. Growth in liquid media (SCD-URA)
containing various concentrations of LS1 was measured
in a Bioscreen C instrument (Growth Curves USA;
Piscataway, NJ). Relative growth rates (∆O.D.600/h)
of JN394t2-4 containing pDED1-yTOP2 (wild-type or
mutant derivatives) were measured for up to 60h after
an initial inoculum of .005 OD600 units. Growth data
were fit to obtain maximum growth rates using the
BGFit webserver [76].

To calculate “DeaD lifespan,” we use the restrictive (i.e.
SC/2% glucose) optical density reading at 60 hours,
normalized to the estimated number of doublings that
have occurred. To estimate the number of doublings, we
use the actual number of doublings in permissive (i.e.
SCRaffGal) medium in the first 24 hours, plus 36 times
the calculated number of doublings per hour derived
from the culture growth from hour 18 to hour 24. This
assumes that the restrictive growth medium does not
become limiting during the course of the assay, an
assumption that is supported by restrictive optical
density readings that are typically in the range of 0.1 to
0.3 at 60 hours. Growth rates expressed as the
reciprocal of the doubling time (1/DT).

LS1 inhibition of hTop2-α was determined by
measuring the effect of LS1 on the ability of hTop2-α to
decatenate kinetoplastid DNA from Crithidia
fasciculata. Human Top2-α was added to 0.2µg of
kDNA (both were purchased from Topogen, Inc; Buena
Vista, CO) in the presence of 1% DMSO (vehicle
control) without or with increasing concentrations of
LS1 as indicated. Samples were incubated at 37°C for
15min, and then reactions were terminated by the
addition of an SDS buffer. Samples were resolved by
1% agarose 1xTAE gel and stained with ethidium
bromide. Decatenated versus intact kDNA species were
quantified by densitometry using GelQuant.NET1.8.2
software.
Final % products were plotted using
KaleidaGraph software.

Inhibition of human Topoisomerase 2-alpha (hTop2α)

TOP2 mutagenesis and isolation of LS1-resistant
yeast

Tissue culture cell growth

A plasmid (YCpDED1-yTOP2) containing yeast TOP2
gene under the control of DED1 promoter and strain
JN394top2-4 (MATa ura3-52 leu2 trp1 his7 ade1-2
ISE2 rad52::LEU2 top2-4) containing a temperature
sensitive allele of TOP2 in a rad52∆ background were
employed [26].
YCpDED1-yTop2 plasmid was
maintained by URA selection. Hydroxylamine
mutagenesis of the plasmid was performed as
previously described [41, 75].
Mutations in the
plasmid copy of the yeast TOP2 gene that retained
function yet were resistant to LS1 were obtained by
selection at the restrictive temperature (35°C) where the
chromosomal TOP2 ts2-4 allele is non-functional by
including 20µM LS1 in the growth media. The
resistance of individual strains carrying TOP2 mutations
was checked by plating spot-dilutions on SCD-URA
plates containing either DMSO carrier or DMSO with
20µM LS1 added. To rule out potential mutations in
the strains as a cause of LS1 resistance, strains were
cured for the pDED1-yTOP2 mutagenized plasmid by
treatment with 5-floroorotic acid (5-FOA), and
subsequently tested for LS1 resistance. Reciprocally,
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All cell lines were grown in monolayer at 37°C in 3%
O2, 5% CO2 and 97% relative humidity in HERA Cell
240 incubators on treated polystyrene cell culture plates
(Corning). Immortalized human fibroblast cells
(HCA2T) were maintained in MEM (ATCC)
supplemented with 15% FBS (Gibco) and 1x Pen/Strep
(Gibco). Human fibrosarcoma cells (HT1080) were
maintained in DMEM (Gibco) supplemented with 10%
FBS (Gibco), 1x Pen/Strep (Gibco) and 1x nonessential
amino acids (Gibco).
Tissue culture cell survival
HT1080 and HCA2T cells were split to a density of 1 ×
105 cells per well of a six well plate 24 hours prior to
treatment with the indicated concentration of DMSO
(Sigma), Doxorubicin (Sigma), Vinblastine (Sigma) and
LS1. All drugs were concurrently applied to the cells.
Cell survival was measured 48 hours after treatment by
counting the adherent cells in each group using a Z2
particle counter (Beckman Coulter). The ratio of
adherent drug-treated cells to adherent cells treated with
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DMSO represents the raw survival. Experiments using
doxorubicin were repeated six times; experiments using
vinblastine were performed in triplicate.

in Multiple Species. Cold Spring Harb Perspect Med.
2015; 5:a025114. doi: 10.1101/cshperspect.a025114
2.

Vermeij WP, Hoeijmakers JH, Pothof J. Genome
Integrity in Aging: Human Syndromes, Mouse Models,
and Therapeutic Options. Annu Rev Pharmacol
Toxicol. 2016; 56:427–45. doi: 10.1146/annurev‐
pharmtox‐010814‐124316

3.

Longo VD, Shadel GS, Kaeberlein M, Kennedy B.
Replicative and chronological aging in Saccharomyces
cerevisiae. Cell Metab. 2012; 16:18–31. doi:
10.1016/j.cmet.2012.06.002

4.

Qin H, Lu M. Natural variation in replicative and
chronological life spans of Saccharomyces cerevisiae.
Exp Gerontol. 2006; 41:448–56.
doi: 10.1016/j.exger.2006.01.007
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enrichment program: a genetic system for facile
replicative life span analysis in Saccharomyces
cerevisiae. Genetics. 2009; 183:413–22. doi:
10.1534/genetics.109.106229

6.

Zhang Y, Luo C, Zou K, Xie Z, Brandman O, Ouyang Q,
Li H. Single cell analysis of yeast replicative aging
using a new generation of microfluidic device. PLoS
One. 2012; 7:e48275.
doi: 10.1371/journal.pone.0048275

7.
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Breitenbach M. A novel assay for replicative lifespan
in Saccharomyces cerevisiae. FEMS Yeast Res. 2004;
5:169–77. doi: 10.1016/j.femsyr.2004.06.015
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Pommier Y, Leo E, Zhang H, Marchand C. DNA
topoisomerases and their poisoning by anticancer
and antibacterial drugs. Chem Biol. 2010; 17:421–33.
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9.

Nitiss JL. DNA topoisomerase II and its growing
repertoire of biological functions. Nat Rev Cancer.
2009; 9:327–37. doi: 10.1038/nrc2608

Western blotting
Anti-yTop2 polyclonal antibodies were purchased from
Topogen (Buena Vista, CO). For the TOP2 tiling
experiments, protein extracts were prepared using the
rapid boiling method [77]. When cells were grown in
minimal media, protein extracts were prepared using the
glass bead method [78].
Secondary antibodies
conjugated to infrared dyes (LI-COR; Lincoln NE) were
employed with an infrared gel scanner (LI-COR;
Lincoln NE) for quantitation of the western blots.
DNA intercalation assay
DNA Topoisomerase I (Top1) –based assay was used to
assess the ability of LS-1 to intercalate. This approach
relies upon linking number changes in supercoiled
plasmid DNA induced by the intercalating molecule
[79] which can be compared to DNA that was not
treated. After treatment with the putative intercalator,
linking number changes can be inferred after relaxation
with DNA Top1. If intercalation occurred, upon
removal of Top1, the final linking number (or state of
supercoiling) will be distinct compared to DNA that
was not treated (control). Molecules that fail to
intercalate appear similar to control samples. DNA was
incubated with DMSO alone or DMSO containing the
indicated amount of doxorubicin, etoposide, or LS-1 for
15min at 25°C, followed by an additional 1h with added
Top1. Next, DNA was extracted with phenol and
chloroform and precipitated with ethanol. Samples
were resolved by electrophoresis through 1% agarose
1xTAE gel and species were quantitated by
densitometry with GelQuant.NET1.8.2 software.
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driven by the GAL1 promoter. The N-terminal ubiquitin
fusion allows modification of the amino terminus of
Cdc6 to reduce protein stability and tighten control over
Cdc6 activity. The ubiquitin moiety is co-translationally
removed by ubiquitin processing proteases, and the
amino acid serving as the new amino terminus of Cdc6
determines its half-life according to the N-end rule [79].

SUPPLEMENTARY MATERIAL
Construction and characterization of an improved
DeaD strain
K6001 is a W303-derived strain that was originally
constructed for use in the study of mother cell-specific
mating type switching [72, 73]. K6001 encodes two
integrated copies of the essential gene CDC6,
independently regulated by the repressible GAL1
promoter and the mother cell-specific HO promoter,
respectively (GAL1:Ub:CDC6 and HO:CDC6).
Previously, we exploited this strain as an alternative to
the standard microdissection method of quantifying
replicative lifespan (RLS), which is labor intensive and
slow [74]. When K6001 cells are grown permissively in
galactose-containing
media
(raffinose/galactose),
GAL1:CDC6 is expressed both in mother and daughter
cells and the culture grows exponentially. When
expression of the GAL1:CDC6 gene is repressed by
glucose, only the mother-cell-specific expression of
HO:CDC6 remains to support growth. Since HO
expression is largely restricted to mother cells,
daughters generally do not divide and growth of the
culture is limited by the RLS of the initial cohort of
mother cells. Since the success of this strategy depends
on the conditional Death of Daughter cells, we call it
the “DeaD” assay. Although promising, K6001 as a
DeaD strain exhibited significant limitations. Its mother
cells cease division on glucose after an average of only
3-4 divisions [74]. K6001 also has a short average
lifespan under permissive conditions, presumably due to
its W303 background (17 generations for K6001 [74],
similar to 20.8 generations for W303R [18]). Early tests
of the assay showed a reduction of DeaD lifespan by
deletion of SIR2 [74] but these tests ignored the fact that
the HO:CDC6 fusion is haploid-specific [75]. Deletion
of SIR2 prevents silencing of the mating type
information at HML and HMR and thus renders cells
pseudo-diploid [76, 77]. After a switch to glucose, sir2Δ
mutants will thus be unable to express either copy of
CDC6 (see below for mechanism of HO gene
expression) and will die rapidly, as was observed [74].
When the opposite mating type information was deleted
from this strain, allowing HO:CDC6 expression to
sustain mother cells in glucose, no difference in DeaD
lifespan was observed between SIR2 and sir2Δ cells
(data not shown). Combined with the other limitations,
this finding indicated that the strategy exemplified by
K6001 would have to be modified before it could be
used as a platform for studying replicative lifespan.

The HO:CDC6 allele in K6001 is an imprecise fusion
of the open reading frame of CDC6 to the HO promoter:
the fusion leaves in place more than 90bp of the CDC6
5’ untranslated region, and all of the 3’ CDC6
untranslated sequences. This construction excludes the
3’ UTR of HO, which appears to play a role in mothercell-specificity of HO expression [81]. For our new
DeaD strain, we therefore created a precise replacement
of the HO open reading frame with CDC6, leaving the
large HO promoter and the HO 3’ untranslated region in
place. This HO:CDC6:HO fusion was integrated into a
strain already carrying GAL1:UbR:CDC6 to create
DeaD strain BB573. BB573 mother cells have improved
survival on glucose compared to K6001 mother cells:
mean RLS increased from 3.4 to 8.3 generations
(p=5.94 x 10-13, Fig. S1B). However, 8.3 generations is
still much shorter than the 26-28 generation mean
lifespan of normal SC288c-derived cells [78].

We began by switching the parental background from
W303 to the longer-lived S288C background [78]. For
galactose-specific CDC6 expression, we chose the
strategy employed in K6001: a ubiquitin:CDC6 fusion

To further improve mother cell survival in glucose, we
sought to increase mother cell expression of HO:CDC6.
Insight into expression of this fusion can be gained from
studies of normal HO. In cells that express the wild-type
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We cloned the GAL:Ub:CDC6 fusion from K6001 to a
plasmid vector. DNA sequencing revealed a tyrosine
codon at the beginning of CDC6, rather than the
expected arginine [73]. Multiple independent clones
from two separately obtained K6001 isolates gave the
same result. According to the N-end rule, tyrosine is
less destabilizing than arginine [79]. Rapid turnover of
GAL1-expressed Ub-Cdc6 is required for efficient death
of daughters after a shift to glucose. Arginine, which is
maximally destabilizing [79], is thus the desired Nterminal residue. All of the clones also carried a
conservative mutation in the ubiquitin moiety: arginine
74 to lysine. We used PCR mutagenesis to correct this
mutation and to change the N-terminal residue of Cdc6
to either arginine or methionine. We then integrated
these alleles, and the original K6001 allele, in place of
the endogenous CDC6 in the S288C-derived strain
Y7092 [80]. Since the GAL:Ub:CDC6 allele is the only
source of CDC6 in these strains, all cells arrest when
transferred to glucose, and the efficiency of this arrest is
a function of the stability of Cdc6. Cells expressing
arginine at the N-terminus of Cdc6 achieved the most
efficient growth arrest. (Fig. S1A). This allele was
incorporated into all subsequent DeaD strains.
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HO endonuclease, mother cells switch mating type at a
rate of ~70% [82]. Inhibition of switching in the
remaining ~30% of mothers is dependent on the
transcriptional repressor Ash1, since deletion of ASH1
increases mother cell switching to 95-100% [72, 82].
These results indicate that Ash1 is normally
incompletely excluded from mother cells. Ideally, Ash1
would be completely partitioned into the incipient
daughter cell (the bud), leaving none in the mother cell
to repress HO expression.

of HMR and SIR2 together gave an intermediate
phenotype (Fig. S3 panels A and C) in both the
microdissection and DeaD lifespan assays. None of
these deletions had significant effects on permissive
growth in galactose, although the hmrΔ sir2Δ strain
exhibited a minor growth defect (Fig. S3 panel D). By
microdissection RLS assay, deletion of HMR slightly
extended RLS: mean RLS increased from 11.3 to 12.1
generations (p=1.5 x 10-2), and maximum increased
from 32 to 45 (Fig. S3 panel B). Deletion of SIR2 in
hmrΔ BB579 cells shortened RLS to a mean of 8.6
generations (p=1.45 x 10-4), with a maximum of 33
generations (Fig. S3 panel A).

ASH1 is expressed at the end of mitosis, when the
transcription factors Swi5 and Ace2 enter the nucleus
and promote ASH1 expression by binding to four
putative Swi5/Ace2 binding sites (predicted by the
nucleotide sequence kGCTGr, where “K” is G or T and
“R” is A or G, [83] in the ASH1 promoter. ASH1
expression is dramatically decreased in swi5 ace2
double mutants [72, 84]. We deleted the Swi5/Ace2
binding sites, either in toto or in pairwise combinations,
in BB573 and assessed the effect on mother and
daughter cell survival on glucose by pedigree analysis
(Fig. S2). Deletion of the 1st two Swi5p binding sites
(ASH1-Δ12) caused too drastic a drop in Ash1: daughter
cell survival dramatically increased (represented by tall
bars in Fig. S2 panel B), compare with parental strain
BB573, Fig S2 panel A). This effect was caused to a
lesser extent by deletion of the middle two sites (ASH1Δ23, Fig. S2 panel C) or of all four binding sites (ASH1Δ14, Fig S2 panel D). In contrast, deletion of the 3rd and
4th Swi5p binding sites produced a strain with enhanced
mother cell survival without increased daughter cell
“escape” (Fig S2 panel E). This strain, ASH1-Δ34, was
renamed BB579 and it and its derivatives were used in
all subsequent work. BB579 has a mean survival of 11.3
generations on glucose (longer than its parental strain,
BB573, p=1.77 x 10-7) corresponding roughly to a
model combining Gompertzian senescence with a
stochastic death rate of 7.5% (Fig. S3 panel A).

The above results demonstrate that SIR2 strains have
longer DeaD assay lifespans than sir2Δ strains in the
improved BB579 background. To test this relationship
further, and to determine whether the DeaD assay is
sensitive not only to lifespan shortening but also to
lifespan extension, we asked whether we could detect a
range of effects on RLS by altering the expression level
of SIR2 with a series of promoter fusions. Replicative
lifespan varies with SIR2 expression level in yeast,
since deletion of SIR2 shortens lifespan and an extra
copy of SIR2 extends it [18]. There is likely to be an
upper limit to lifespan extension by up-regulation of
SIR2, however, since SIR2 overexpression from the
GAL1 promoter causes toxicity and elevated rates of
chromosome loss [86]. For our test, we used PCR-based
integration to replace the endogenous SIR2 promoter
with the CYC, ADH, TEF, or GPD promoter [87] in an
HMR-deleted BB579 derivative. DeaD assay lifespan of
the resulting strains paralleled the predicted promoter
strength (CYC<ADH<TEF<GPD, [87]), with strains
carrying the strongest two promoters showing extension
of DeaD assay lifespan (Fig. S4 panel C).
As expected if strong overexpression of SIR2 is toxic,
the GPDpr:SIR2 fusion, which we expect to be more
strongly expressed than the TEFpr:SIR2 fusion [87],
confers no additional advantage for lifespan (Fig. S4
panel C). None of these deletions had significant affects
on permissive growth in galactose, although the hmrΔ
sir2Δ strain exhibited a minor growth defect (Fig. S3
panel B).

Yeast cells become sterile near the end of their lifespan
due to de-repression of the silent HM mating type loci
and the resulting pseudo diploidy [85]. De-repression of
the HM loci in a DeaD strain will result in failure to
express haploid-specific HO:CDC6, as discussed above,
and which might cause premature death in aging cells
and an artificially short lifespan. To investigate the
potential benefit of preventing pseudo diploidy by
deleting one of the two mating type loci, HMR, we
deleted HMR in SIR2 and sir2Δ BB579 cells. We
performed microdissection (Fig. S3 panels A and B)
and DeaD lifespan assays (Fig. S3 panel C) of parental
BB579 (HMR), hmrΔ, sir2Δ and hmrΔ sirΔ strains.
Deletion of SIR2 alone produced an extremely short
apparent RLS, presumably due to repression of HO
expression resulting from pseudo diploidy, and deletion
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In a parallel set of experiments, we replaced the
endogenous SIR2 promoter with the same promoter
series in a wild-type S288C strain and measured
replicative lifespan using the standard microdissection
assay. The results (Fig.4S Panel D) are a striking
parallel to the DeaD assay findings. The TEF promoter
extended mean lifespan by a robust 45%, while the
stronger GPD promoter showed a lesser extension of
22%. We conclude that improvements to K6001
engineered into BB579 allow recapitulation of key
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features of yeast aging using high throughput capable
liquid growth-based assays, including lifespan shorte-

ning and extension by under- and overexpression of
SIR2.

Figure S1. Characterization of improved DeaD strain BB573. (A) Arrest of GAL:Ub:CDC6 strains in
glucose is dependent on the N‐terminal residue of Cdc6p. Cells were transferred to glucose at time 0 and
growth arrest was monitored by measuring the culture OD600. The letter indicates the N‐terminal Cdc6p
residue: M: methionine, Y: tyrosine, or R: arginine. (B) BB573 mother cells have improved survival on
glucose compared to K6001 mother cells: mean RLS increased from 3.4 to 8.3 generations (p=5.94 x 10‐13).
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Figure S2. Pedigree analysis of BB573 and derivatives carrying ASH1 promoter deletions. Strains were
grown in a galactose‐containing medium to mid‐log phase and arrayed on glucose (SCD) plates for microdissection.
Divisions of mother cells are represented on the x axis, and divisions of daughter cells by the height of the bars.
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Figure S3. The effect of hmr and sir2 deletions on mother cell survival and DeaD lifespan in new DeaD assay strain
BB579. (A) Survival of BB579 and its hmr∆ hmr∆sir2∆, and sir2∆ derivatives on glucose. Strains were grown to mid‐log phase in a
galactose‐containing medium and arrayed on glucose (SCD) plates. Mother cell survival was determined by microdissection. For
comparison, models of BY4741 (“x”s) and its sir2∆ derivative (open circles) with a 7.5% rate of stochastic death are included. (B)
Mean and maximum replicative lifespans from (A). (C) Representative restrictive liquid cultures of the same four strains. (D)
Parallel permissive liquid cultures. (E) Relative DeaD assay lifespans of the four strains, using data from (C) and (D) together with
two more independent experiments. Error bars are +/‐ one standard error of the mean of the three experiments.
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Figure S4. DeaD assay recapitulates microdissection replicative lifespan measurement. (A) In the traditional
microdissection replicative lifespan method the DEAD strain deletion of SIR2 results in a drop in average lifespan from
15.5 generations (□ Parental) to 10.5 generation (X sir2∆), a 32.25% decrease. (B) In the DeaD assay the average lifespan
decrease (* measured at 60hrs) from optical density of 0.331 (□ Parental) to 0.116 (X sir2∆), a 65% drop in lifespan. (C) &
(D) When SIR2 expression levels are varied by promoters of varying strength from low (CYC), normal (ADH) and high (TEF),
relative and mean lifespan as reported by the DeaD assay also show reduced, normal, and extended levels.

Figure S5. DeaD assay reports replicative lifespan for
several strains that show reduced lifespan in the
traditional microdissection assay. Yeast strains were
obtained from the gene deletion collection. Replicative
lifespan (%) for both microdissection and DeaD assay were
determined as described in Methods.
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Figure S6. Map of LS1 resistant hypomorphic top2 alleles. UCSF
Chimera was used to display the X‐ray structure of yeast Top2 and map the
location of each of the LS1 resistant hypomorphic alleles onto the protein
structure. The dispersed locations of each mutation are consistent with
other top2 alleles previously found to confer broad resistance to Top2
poisons such as DOX or ETOP.
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